Anterix (ATEX) Financials

Anterix (NASDAQ: ATEX) showed a sharp turnaround in the latest quarter, but the broader multi-year picture remains mixed. In Q4 2026, the company reported revenue of $2.0 million and net income of $18.5 million, helped by unusually large non-operating items and a strong contribution from divestitures. That is a major improvement from the loss of $6.6 million in Q3 2026 and from prior-year losses. However, investors should note that the business still generates very little recurring revenue relative to its expense base, and results can be heavily influenced by one-time items.

Over the last several years, ATEX has generally operated at a loss at the operating level. Revenue has remained low and uneven, while SG&A, marketing, and R&D expenses have consistently exceeded gross profit. The company has only periodically posted positive net income, often because of large special gains, investment income, or other non-core items rather than sustained operating profitability.

Cash flow is the most important positive trend in the recent data. Operating cash flow improved meaningfully in the latest quarter, and the balance sheet still carries a substantial cash position. That gives the company time to execute its strategy, even though operating profits are inconsistent.

• Q4 2026 net income jumped to $18.5 million, a big turnaround from a $6.6 million loss in Q3 2026.
• Operating cash flow was strong in Q4 2026 at $15.5 million, compared with negative $8.3 million in Q3 2026.
• The company ended Q3 2026 with $29.5 million in cash and equivalents, providing near-term liquidity.
• Book equity remained positive at $236.0 million in Q3 2026, with liabilities well below total assets.
• Q2 2026 showed a large profit swing, with net income of $53.5 million and EPS of $2.86, though much of the improvement appears tied to non-operating items.
• Revenue has remained relatively small and fairly steady, rising from about $1.4 million-$1.6 million in most recent quarters to $2.0 million in Q4 2026.
• The company’s asset base is dominated by intangible assets and deferred revenue-related balances, which is common for a licensing-style business but can make quality of earnings harder to judge.
• Cash flow has been lumpy over time, with several quarters showing strong inflows from working capital and divestitures rather than purely from core operations.
• ATEX continues to show a recurring pattern of operating losses despite occasional reported profits.
• Operating expenses remain high relative to revenue, with SG&A and marketing alone often many times larger than quarterly sales.

Balance sheet leverage looks manageable, but not especially light. As of Q3 2026, total liabilities were about $181.1 million against total assets of $417.0 million. Short-term debt was $9.2 million, but the larger issue is the company’s dependence on deferred revenue and other noncurrent liabilities, which can constrain flexibility if operations weaken.

Bottom line: Anterix’s latest quarter was clearly positive on headline earnings and cash flow, but investors should focus on whether the company can convert these gains into a more stable, recurring operating model. Until then, ATEX looks like a cash-rich but still inconsistent business with earnings that can swing sharply from quarter to quarter.